Males (a; t(21)=1.970, p=0.0698) and females (c; t(37)=5.074, p<0.0001) administered Ex-4 during probe trials completed fewer trials than their respective controls, although this reached significance only in females. The GLP-1R agonist did not alter the total number of reversals in probe trials in males (b; t(21)=0.6041, p=0.5522) but did non-significantly decrease the number of reversals in females (d; t(37)=1.939, p=0.0603). † p<0.1; **** p<0.0001